# Marksans Pharma (NSE: MARKSANS) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/MARKSANS · Pivot · prices to 22 Oct 2026

Marksans Pharma (NSE: MARKSANS) closed at ₹295.80 on 22 Oct 2026, down 0.89% on the day. With a market capitalisation of ₹13,343 Cr, it ranks 469th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.

At its last close the stock traded at 32.1× trailing earnings, against a return on equity of 13.8% in FY26. Over the past year the share price has risen 62.6%. Its 52-week range is ₹155.00 (30 Mar 2026) to ₹350.95 (24 Sep 2026); the last close is 15.7% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹856 Cr (+20.8% year on year) and net profit ₹149 Cr (+64.3%), on a consolidated basis. Promoters held 43.87% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹295.80 |
| Market cap | ₹13,343 Cr |
| P/E (trailing) | 32.1 |
| ROE | 13.8% (FY26) |
| ROCE | 17.5% (FY26) |
| Debt to equity | 0.01 |
| 52-week high | ₹350.95 (24 Sep 2026) |
| 52-week low | ₹155.00 (30 Mar 2026) |
| 1-year return | +62.6% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹856 Cr | +20.8% | ₹149 Cr | +64.3% | ₹3.27 |
| Q3 FY26 | ₹754 Cr | +10.6% | ₹114 Cr | +8.2% | ₹2.50 |
| Q2 FY26 | ₹720 Cr | +12.2% | ₹99 Cr | +1.4% | ₹2.17 |
| Q1 FY26 | ₹620 Cr | +5.0% | ₹58 Cr | −34.7% | ₹1.29 |
| Q4 FY25 | ₹708 Cr | +26.5% | ₹91 Cr | +16.9% | ₹2.00 |
| Q3 FY25 | ₹682 Cr | +16.3% | ₹105 Cr | +26.6% | ₹2.31 |
| Q2 FY25 | ₹642 Cr | +20.8% | ₹98 Cr | +16.6% | ₹2.13 |
| Q1 FY25 | ₹591 Cr | +18.1% | ₹89 Cr | +26.4% | ₹1.96 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹2,623 Cr | ₹383 Cr |
| FY24 | ₹2,177 Cr | ₹315 Cr |
| FY23 | ₹1,852 Cr | ₹265 Cr |
| FY22 | ₹1,491 Cr | ₹187 Cr |
| FY21 | ₹1,376 Cr | ₹239 Cr |
| FY20 | ₹1,134 Cr | ₹121 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 43.87%
- Foreign institutions: 17.47%
- Domestic institutions: 6.19%
- Non-institutions: 32.47%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Vijaya Diagnostic Centre](https://app.pivotnow.in/stock/VIJAYA) | ₹1,382.60 | ₹14,324 Cr | 82.5 | 18.1% |
| [Indegene](https://app.pivotnow.in/stock/INDGN) | ₹577.95 | ₹14,171 Cr | 34.8 | 12.8% |
| [Natco Pharma](https://app.pivotnow.in/stock/NATCOPHARM) | ₹785.00 | ₹14,063 Cr | 9.9 | 15.4% |
| [Concord Biotech](https://app.pivotnow.in/stock/CONCORDBIO) | ₹1,298.00 | ₹13,294 Cr | 52.4 | — |
| [CORONA Remedies](https://app.pivotnow.in/stock/CORONA) | ₹2,024.70 | ₹12,500 Cr | 66.8 | 24.8% |
| [Rainbow Childrens Medicare](https://app.pivotnow.in/stock/RAINBOW) | ₹1,205.70 | ₹12,184 Cr | 43.9 | 16.9% |

## Questions and answers

### What is the share price of Marksans Pharma today?

Marksans Pharma (NSE: MARKSANS) last closed at ₹295.80 on 22 Oct 2026. Its 52-week high is ₹350.95 and its 52-week low is ₹155.00.

### What is the market cap of Marksans Pharma?

Marksans Pharma's market capitalisation is ₹13,343 Cr (₹13,343 Cr) at the 22 Oct 2026 close, ranking 469th among the NSE companies Pivot tracks.

### What is the P/E ratio of Marksans Pharma?

Marksans Pharma trades at a trailing P/E of 32.1. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 52.4.

### What is the ROE and ROCE of Marksans Pharma?

Return on equity was 13.8% in FY26 and return on capital employed was 17.5% in FY26 (consolidated figures).

### Is Marksans Pharma a debt-free company?

Marksans Pharma is close to debt-free: its debt-to-equity ratio was 0.01 in FY26.

### What were Marksans Pharma's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Marksans Pharma reported revenue of ₹856 Cr, +20.8% year on year, and net profit of ₹149 Cr, +64.3% year on year.

### How has Marksans Pharma stock performed over the last year?

Marksans Pharma's share price has risen 62.6% over the past year, +22.2% over three months and −12.5% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Marksans Pharma?

As of 30 Jun 2026: promoters 43.87%, foreign institutions 17.47%, domestic institutions 6.19%, non-institutions 32.47%.

### Who are Marksans Pharma's competitors?

The listed Pharma & Healthcare companies closest to Marksans Pharma by market cap are Vijaya Diagnostic Centre, Indegene, Natco Pharma, Concord Biotech, CORONA Remedies and Rainbow Childrens Medicare.

### Is Marksans Pharma a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Marksans Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MARKSANS against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.